Veradermics MANE R&D
R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veradermics 's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veradermics 's R&D?
- Veradermics (MANE) reported R&D of $20.93M in Q1 2026.
- How has Veradermics 's R&D changed year-over-year?
- Veradermics 's R&D increased by 82.8% year-over-year, from $11.45M to $20.93M.
- What does R&D mean?
- The total amount spent on research and development activities.
- How do you interpret R&D?
- Higher spending indicates aggressive investment in the product pipeline, while lower spending may suggest a focus on cost-cutting or a mature product portfolio.
- How does R&D compare across companies?
- Biotech peers typically show high R&D intensity relative to revenue, often exceeding 50-100% of operating expenses during clinical trial phases.